Who is sponsoring NCT05506748?

NCT05506748 is sponsored by Chitwan Medical College.

What drugs are being tested in NCT05506748?

Interventions in NCT05506748: pantients undergoing pancreaticoduodenectomy.

What condition does NCT05506748 study?

NCT05506748 studies Hemoglobins, Albumins, Platelets, Lymphocytes, Morbidity, Mortality, Whipples Procedure.

Is NCT05506748 still recruiting?

NCT05506748 is currently completed. Last updated 18 August 2022.

Last reviewed 2022-08-18 · How we verify

NCT05506748

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Association Between Preoperative HALP and Immediate Postoperative Outcomes

Completed Last updated 18 August 2022

What this trial tests

trial testing pantients undergoing pancreaticoduodenectomy in Hemoglobins in 22 participants. Completed in 20 April 2022.

Timeline

20 April 2021

Primary endpoint
20 April 2022

20 April 2022

Quick facts

Lead sponsor	Chitwan Medical College
Status	Completed
Study type	OBSERVATIONAL
Enrollment	22
Start date	20 April 2021
Primary completion	20 April 2022
Estimated completion	20 April 2022
Sites	1 location across Nepal

Drugs / interventions tested

pantients undergoing pancreaticoduodenectomy

Conditions studied

Hemoglobins — all drugs for Hemoglobins →
Albumins — all drugs for Albumins →
Platelets — all drugs for Platelets →
Lymphocytes — all drugs for Lymphocytes →

Sponsor

Chitwan Medical College

Who can join

Adults 15 to 80, any sex, with Hemoglobins or Albumins. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Multiple inflammation-based prognostic scores have been developed for the prediction of perioperative morbidity and mortality following pancreaticoduodenectomy (PD). Preoperative "Hemoglobin, Albumin, Lymphocytes and Platelets index (HALP)" is one of the promising inflammatory markers that has emerged as a predictor of postoperative survival. To date, no study has been done with preoperative HALP to predict 30days morbidity and mortality. Is there any association between Preoperative HALP (hemoglobin, albumin, lymphocyte, and platelet) and 30 days post operative morbidity and mortality in patients undergoing Pancreaticoduodenectomy?

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Chitwan Medical College trials

Trials by the same sponsor.

NCT04387487 — Does Showing Video Information About Spinal Anesthesia Relieves Patient Anxiety? · NA · unknown
NCT05366907 — Open Cholecystectomy Among Patients Undergoing Laparoscopic Cholecystectomy. · completed
NCT03200002 — Cyclophosphamide Versus Mycophenolate Mofetil in Lupus Nephritis · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05506748 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chitwan Medical College
Last refreshed: 18 August 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05506748.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing